Permeability classification of representative fluoroquinolones by a cell culture method

AAPS Journal

Volumn 6, Issue 2, 2004, Pages

  Volpe, Donna A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Biopharmaceutics classification system; Caco 2; Fluoroquinolones; Permeability

Indexed keywords

EID: 34248682649     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
2. Center for Drug Evaluation and Research. Food and Drug Administration. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Available at: http://www.fda.gov/cder/guidance/3618fnl.pdf. Accessed August 2000.
3. Volpe DA, Ciavarella AB, Asafu-Adjaye EB, Ellison CD, Faustino PJ, Yu LX. Method suitability of a Caco-2 cell model for drug permeability classification [abstract]. AAPS PharmSci. 2001; 3(S1). Available at: http://www.aapspharmaceutica.com/search/abstract_view. asp?id= 385&ct=01 Abstracts.
4. Owens RC, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am. 2000;84:1447-1469.
5. Hooper DC. Mode of action of fluoroquinolones. Drugs. 1999;58(suppl 2):6-10.
6. Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy. 2000;20:417-428.
7. Lode H, Hoffken G, Boeckk M, Deppermann N, Bomer K, Koeppe P. Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother. 1990;26(suppl B):41-49.
8. Cipro® (ciprofloxacin hydrochloride tablets) [product information]. West Haven, CT: Bayer Corporation; 2000.
9. Levaquin® (levofloxacin tablets/injection) [product information]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; 2000.
10. Maxaquin® (lomefloxacin hydrochloride tablets) [product information]. Buffalo Grove, IL: Unimed Pharmaceuticals; 1999.
11. Floxin® (ofloxacin tablets) [product information]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc; 1998.
12. Bergan T. Pharmacokinetics of fluorinated quinolones. In: Andriole VT, ed. The Quinolones. London, UK: Academic Press; 1988:119-152.
13. Cavet ME, West M, Simmons NL. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 1997;121:1567-1578.
14. Griffiths NM, Hirst BH, Simmons NL. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J Pharmacol Exp Ther. 1994;269:496-502.
15. Griffiths NM, Hirst BH, Simmons NL. Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. Br J Pharmacol. 1993;108:575-576.
16. Yamaguchi H, Yano I, Saito H, Inui K. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. Eur J Pharmacol. 2001;431:297-303.
17. Yamaguchi H, Yano I, Hashimoto Y, Inui KI. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. J Pharmacol Exp Ther. 2000;295:360-366.
18. Awadallah B, Wahl MA. Transport of ofloxacin enantiomers in the Caco-2-TC7 cell line [abstract]. AAPS PharmSci. 2002; 4(S1). Abstract W5049. Available at: http://www.aapspharmsci.org.
19. Rodríguez-Ibáñez M, Nalda-Molina R, Montala-Montero M, Bermejo MV, Merino V, Garrigues TM. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparafloxacin: in vitro and in situ inhibition studies. Eur J Pharm Biopharm. 2003;55:241-246.